login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

New drug may block the effects of traumatic brain injury


Wednesday, 22 Feb 2012 15:20

A new drug called clazosentan is showing promise in blocking the harmful effects of traumatic brain injury in rats, according to a study to be presented at the American Academy of Neurology’s 64th Annual Meeting in New Orleans, USA, (21–28 April 2012).


“There are currently no primary treatments for traumatic brain injury, so this research provides hope that effective treatments can be developed,” said study author Michael Kaufman, a second year medical student at Wayne State University School of Medicine in Detroit and a member of the American Academy of Neurology. The principal investigator on the study is Christian Kreipke, also from Wayne State University School of Medicine.


Traumatic brain injury causes a decrease in blood flow in the cerebrum of the brain, which if prolonged, can cause permanent cell dysfunction and death. A receptor in the brain called endothelin receptor (ETrA) contributes to the restriction of blood flow as early as four hours after a brain injury. The new drug, called clazosentan, is thought to specifically block these receptors.


Researchers gave brain-injured rats the drug clazosentan through an intravenous line at several different points in time after the injury. Next, they measured the rat’s blood flow in the hippocampus and sensory motor cortex with an MRI brain scan and tested their behavior in learning a maze.


Preliminary data from the study found that clazosentan decreased the effects of the traumatic brain injury on blood flow to the hippocampus by 25% at four hours and 23% at 48 hours after traumatic brain injury. However, giving the rats the drug at 12 hours post-injury caused some to improve, while others worsened or remained the same. In the trial, the drug was most effective when given at two hours post-injury and again at 24 hours after the trauma. The rats also performed better on the maze test when given the drug at two and 24 hours post-injury.


“This research is the foundation for future clinical trials that will investigate the possibilities of using clazosentan in the treatment of traumatic brain injury,” said Kaufman.


The study was supported by the American Academy of Neurology, the National Institutes of Health, and the US Department of Veterans Affairs.




Add New Comment

Most popular


MR CLEAN: expert opinion
Tuesday, 18 Nov 2014
Since the first presentation of data at the World Stroke Congress, the MR CLEAN trial has sent a ripple across the entire neurointerventional arena, raising questions about the future of stroke ... MR CLEAN: expert opinion

MR CLEAN: Better outcomes with intervention in ischaemic stroke patients
Thursday, 18 Dec 2014
For the first time, the Multicentre randomised clinical trial of endovascular treatment for acute ischaemic stroke in the Netherlands (MR CLEAN) has shown better outcomes in favour of intervention in ... MR CLEAN: Better outcomes with intervention in ischaemic stroke patients

Silk Road Medical unveils data from the ROADSTER trial
Wednesday, 26 Nov 2014
Silk Road Medical’s 30-day outcomes from the ROADSTER IDE study were presented at the Late Breaking Clinical Trials Session at the 2014 Vascular InterVentional Advances Meeting in Las Vegas, with ... Silk Road Medical unveils data from the ROADSTER trial

Features


Impact“ful” moments
Friday, 05 Dec 2014
Once a year, in almost ritualised fashion, the editors of peer-reviewed journals anxiously await publication of the Thomson Reuters Impact Factor. Journals in the “neuro” space are no exception to ... Impact“ful” moments

The changing face of traumatic brain injury: Life beyond the guidelines
Tuesday, 18 Nov 2014
András Büki and Andrew Maas write that despite considerable efforts both in basic and clinical research, there has not been a major breakthrough in the care of the head injured in the last three ... The changing face of traumatic brain injury: Life beyond the guidelines

Profiles


Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Mauricio Castillo
Monday, 14 Jul 2014
Mauricio Castillo is a professor of Radiology and chief, Division of Neuroradiology, University of N... Mauricio Castillo

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions